SNVP 32
Alternative Names: SNVP-32Latest Information Update: 03 Oct 2024
At a glance
- Originator Immorta Bio
- Class Antineoplastics; Cell therapies; Immunotherapies; Senotherapeutics
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 11 Sep 2024 SNVP 32 is available for licensing as of 11 Sep 2024. https://www.immortabio.com/#collaboration (Immorta Bio pipeline, September 2024)
- 11 Sep 2024 Preclinical trials in Pancreatic cancer in USA (Parenteral) prior to September 2024 (Immorta Bio pipeline, September 2024)